Skip to main content

Table 3 Cost-effectiveness and threshold gel prices under variations to introduction scenario assumptions and sensitivity analysis [2012 USD]

From: Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices

Variations to introduction scenario

      
 

Reduction in condom use

Coverage

Consistency of gel use

HIV efficacy

$/DALY averted

% change

Threshold price

% change

Baseline

0%

30%

72%

54%

$297

 

$0.12

 
 

5%

30%

72%

54%

$586

97%

$0.03

-74%

 

10%

30%

72%

54%

$1,219

310%

cannot be achieved

 
 

0%

60%

72%

54%

$285

-4%

$0.13

5%

 

0%

60%

50%

54%

$468

58%

$0.03

-78%

 

0%

30%

72%

83%

-$14

-105%

$0.33

166%

Cost sensitivity analysis

       

1 dose per sex-act

   

$78

-74%

$0.25

100%

Discount rate 0%

    

-$243

-182%

$0.43

244%

Discount rate 6%

    

$525

77%

cannot be achieved

 

ART costs 10% lower

   

$344

16%

$0.10

-21%

ART costs 25% lower

   

$413

39%

$0.06

-53%

All other input costs 25% higher

   

$402

35%

$0.06

-48%

All other input costs 25% lower

   

$193

-35%

$0.18

48%

Input +25%, ART-10%

   

$448

51%

$0.04

-69%

Input +25%, ART-25%

   

$518

74%

-$0.00

-100%

ART coverage 80%

   

$163

-45%

$0.24

90%